| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 584 | 2019 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 314 | 2020 |
| Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors JR Goodhand, M Wahed, JE Mawdsley, AD Farmer, Q Aziz, DS Rampton Inflammatory bowel diseases 18 (12), 2301-2309, 2012 | 277 | 2012 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 262 | 2021 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 182 | 2021 |
| Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease JR Goodhand, N Kamperidis, A Rao, F Laskaratos, A McDermott, ... Inflammatory bowel diseases 18 (3), 513-519, 2012 | 177 | 2012 |
| Systematic review: Clostridium difficile and inflammatory bowel disease JR Goodhand, W Alazawi, DS Rampton Alimentary pharmacology & therapeutics 33 (4), 428-441, 2011 | 157 | 2011 |
| Adolescents with IBD: the importance of structured transition care J Goodhand, CR Hedin, NM Croft, JO Lindsay Journal of Crohn's and Colitis 5 (6), 509-519, 2011 | 155 | 2011 |
| Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study JR Goodhand, FIS Greig, Y Koodun, A McDermott, M Wahed, ... Inflammatory bowel diseases 18 (7), 1232-1239, 2012 | 148 | 2012 |
| Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease GJ Walker, JW Harrison, GA Heap, MD Voskuil, V Andersen, ... Jama 321 (8), 773-785, 2019 | 140 | 2019 |
| COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, ... The lancet Gastroenterology & hepatology 7 (4), 342-352, 2022 | 133 | 2022 |
| Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease N Heerasing, B Thompson, P Hendy, GA Heap, G Walker, R Bethune, ... Alimentary pharmacology & therapeutics 45 (5), 660-669, 2017 | 129 | 2017 |
| Inflammatory bowel disease in young people: the case for transitional clinics J Goodhand, R Dawson, M Hefferon, N Tshuma, G Swanson, M Wahed, ... Inflammatory bowel diseases 16 (6), 947-952, 2010 | 124 | 2010 |
| Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity CC Suiter, T Moriyama, KA Matreyek, W Yang, ER Scaletti, R Nishii, ... Proceedings of the National Academy of Sciences 117 (10), 5394-5401, 2020 | 105 | 2020 |
| Factors associated with thiopurine non‐adherence in patients with inflammatory bowel disease JR Goodhand, N Kamperidis, B Sirwan, L Macken, N Tshuma, Y Koodun, ... Alimentary pharmacology & therapeutics 38 (9), 1097-1108, 2013 | 94 | 2013 |
| Does psychological counseling alter the natural history of inflammatory bowel disease? M Wahed, M Corser, JR Goodhand, DS Rampton Inflammatory bowel diseases 16 (4), 664-669, 2010 | 92 | 2010 |
| Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience S Honap, D Chee, TP Chapman, M Patel, AJ Kent, S Ray, E Sharma, ... Journal of Crohn's and Colitis 14 (10), 1385-1393, 2020 | 84 | 2020 |
| Management of stress in inflammatory bowel disease: a therapeutic option? JR Goodhand, M Wahed, DS Rampton Expert review of gastroenterology & hepatology 3 (6), 661-679, 2009 | 83 | 2009 |
| Integrated models of care in managing inflammatory bowel disease: a discussion AA Mikocka-Walus, JM Andrews, CN Bernstein, LA Graff, JR Walker, ... Inflammatory bowel diseases 18 (8), 1582-1587, 2012 | 80 | 2012 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 76 | 2022 |
Nicholas KennedyConsultant Gastroenterologist and Honorary Clinical Senior Lecturer, University of Exeter在 exeter.ac.uk 的电子邮件经过验证
